Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 4187-4191

  Maruyama, Michio ^a   Nagahama, Takeshi ^a   Yuasa, Yasuhito ^a  

^a NONE

Author keywords

CPT 11; Intraperitoneal chemotherapy; Liver metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; COLON CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; SPLEEN;

EID: 0032806385     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ohno R, Okada T, Masaoka T, et al: An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907-1912, 1990.
2. Rougier P, Cutsem EV, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998.
3. Futatsuki K, Wakui A, Nakao I, et al: Late phase II study of irinotecan hydrochloride (CPT-11 in advanced gastric cancer. Jpn J Cancer Chemother 21: 1033-1038, 1994.
4. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 10: 1225-1229, 1992.
5. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10: 16-21, 1992.
6. Takeuchi S, Takamizawa H, Takeda Y, et al: Clinical study of CPT-11, a camptothecin derivative, on gynecological malignancy. Proc. Am. Soc. Clin. Oncol 10: 189-XXX, 1990.
7. Moertel CG, Schutt AJ, Reitemeier RJ, et al: Phase II study of camptothecin in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101, 1992.
8. Shimoda Y, Yoshino M, Wakui A. et al: Phase II study on CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11: 909-913, 1993.
9. Araki E, Ishikawa M, Iigo M, et al: Rerationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84: 697-702, 1993.
10. Kaneda N, Nagata T, Furuta T, et al: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715-1720, 1990.
11. Myers CE, Collins JM: Pharmacology of intraperitoneal chemotherapy. Cancer Investigation 1: 395-407, 1983.
12. Speyer JL, Sugarbaker PH, Collins JM, et al: Portal level and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41: 1916-1922, 1981.
13. Archer S, Gray B: Intraperitoneal 5-fluorouracil infusion for treatment of both peritoneal and liver micrometastasis. Surgery 108: 502-507, 1990.
14. Maruyama M, Takamatsu S, Sugano N, et al: Experimental study on intraperitoneal sequential MTX/5-FU therapy for peritoneal seeding in comparison with intravenous administration. Jpn J Cancer and Chemother 24: 2131-2136, 1997.
15. Maruyama M, Sugano N, Ebuchi M, et al: Experimental study on intraperitoneal administration of 5-fluorouracil for liver metastasis in comparison with intravenous administration. Jpn J Cancer and Chemother, In press
16. Sugarbaker PH, Cunliffe WJ, Belliveau J, et al: Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Seminars in Oncology 16: 83-97, 1989.
17. Speyer J: The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancy. Semin Oncol 12: 23-28, 1985.
18. Guichard S, Chatelut E, Lochon I, et al: Comparison of the pharmacokinetics and efficiency of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 42: 165-70, 1998.
19. Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN-38, a metabolite of the camptothescin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191, 1991.
20. Tanizawa A, Fujiomori A, Fujimori Y, et al: Comparison of topoisomerase I inhibition, DNA damage and cytotxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836-842, 1994.
21. Kawano Y, Furuta T, Aonuma M, et al: Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192-198, 1991.
22. van Ark-Otte J, Keddle MA, van der Vijgh WJF, et al: Determinants of CPT-11 and SN-38 activities in human lung cancer cells. British J Cancer 77: 2171-2176, 1998
23. Los G, Mutsaers PHA, van der Vigh WJF, et al: Direct diffusion of cisdiamine-dichloroplatinum (II in intraperitoneal rat tumor after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49: 3380-3381, 1989.
24. Collins JM, Dedrick RL, Flessner MF, et al: Concentration-dependent disappearance of fluorouracil from peritoneal fluid in the rat: Experimental observations and distributed modeling. J Pharm Sci 71: 735-738, 1982.
25. Howell SB, Pfeifle CE, Olshen RA: Intraperitoneal chemotherapy with melphalan. Ann Intern Med 101: 14-18, 1984.